Maxim Group analyst Naz Rahman has reiterated their bullish stance on ALIM stock, giving a Buy rating today.
Naz Rahman has given his Buy rating due to a combination of factors including Alimera’s impressive first-quarter revenue growth and the company’s strong sales performance, particularly in the U.S. and international markets. This growth is being driven by successful product sales and strategic acquisitions, such as Yutiq, which is expected to bolster revenue through cross-selling alongside Alimera’s existing product, Iluvien.
Rahman’s confidence is further bolstered by Alimera’s self-financing capability, efficient management that has reiterated positive revenue guidance, and an upward trend in adjusted EBITDA margins. The products’ competitive positioning, with longer duration of action and safety profiles, also contributes to the favorable outlook. Overall, these indicators suggest a path toward improved profitability and justify the Buy rating assigned to Alimera’s stock (ALIM).
According to TipRanks, Rahman is an analyst with an average return of -9.3% and a 31.07% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Palisade Bio, and PainReform.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Alimera (ALIM) Company Description:
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Read More on ALIM:
